Placebo to match AZD6234

DRUG4 trials

Sponsors

AstraZeneca AB

Conditions

Obesity or OverweightObesity or Overweight Weight-Related Comorbidity with/without Diabetes MellitusObesity or overweight Diabetes MellitusOverweight and obesityType 2Weight-Related Comorbiditywithout Diabetes Mellitus

Phase 1

A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 Monotherapy and Co-administration of AZD9550 and AZD6234 in Participants Living with Obesity and Overweight with or without Type 2 Diabetes Mellitus

Active, not recruitingCTIS2023-504215-32-00

AstraZeneca ABOverweight and obesity

Start: 2023-09-28Target: 101Updated: 2025-10-15

Phase 3

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 as an Adjunct to Incretin-based Therapies in Participants with Obesity or Overweight with at Least One Weight-Related Comorbidity With or Without Type 2 Diabetes Mellitus

Not yet recruitingCTIS2025-523295-23-00

AstraZeneca ABObesity or Overweight Weight-Related Comorbidity with/without Diabetes Mellitus, Type 2

Target: 35Updated: 2026-09-21

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Type 2 Diabetes Mellitus and Obesity or Overweight

Not yet recruitingCTIS2025-524616-11-00

AstraZeneca ABObesity or overweight Diabetes Mellitus, Type 2

Target: 195Updated: 2026-10-06

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Obesity or Overweight With at Least One Weight Related Comorbidity Without Type 2 Diabetes Mellitus

Not yet recruitingCTIS2025-523379-41-00

AstraZeneca ABObesity or Overweight, Type 2, Weight-Related Comorbidity +1

Target: 627Updated: 2026-10-09